[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Floreani A, Boninsegna S, Lobello S, Caroli D, Fagiuoli S: Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. Gastroenterol Clin Biol; 2006 Feb;30(2):307-9
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lamivudine is a nucleoside analogue with a potent antiviral activity used as prophylaxis against hepatitis B virus reactivation in patients with chronic HBV infection receiving chemotherapy.
  • No standard guidelines exist, however, for the duration of lamivudine treatment.
  • We report a clinical case of a 56-year-old patient with HBeAg-negative cirrhosis who developed a multiple myeloma.
  • He was treated with lamivudine for 1 year while receiving chemotherapy and a subsequent bone marrow transplant.
  • Complete remission from multiple myeloma was achieved.
  • The patient rapidly developed fatal decompensation with septicemia and renal failure.
  • In conclusion, this case shows that physicians should avoid discontinuing nucleoside therapy in patients with HBV infection who undergo immunosuppression for concomitant neoplastic conditions.
  • [MeSH-major] Hepatitis B / drug therapy. Lamivudine / therapeutic use. Multiple Myeloma / complications. Reverse Transcriptase Inhibitors / therapeutic use. Virus Activation

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565668.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


2. Willmott F, Agarwal N, Heath M, Stevens J, Chakravarti S: Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma diagnosed in pregnancy.
  • Plasma cell myeloma (PCM) is an essentially incurable neoplastic disorder of terminally differentiated B cells.
  • The clinical picture is one of bone marrow failure, due to infiltration of the marrow by malignant plasma cells; renal failure due to damage to renal tubules by the excess light chains and pain due to lytic lesions of the bones.
  • [MeSH-major] Multiple Myeloma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. Cesarean Section. Disease Progression. Female. Fetal Growth Retardation / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Male. Neoplasm Staging. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / drug therapy. Puerperal Disorders / pathology. Remission Induction

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004 Jun;86-A(6):1284-8 [15173303.001]
  • [Cites] Blood. 1966 Jul;28(1):102-11 [5944257.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):811-20 [5742077.001]
  • [Cites] West Indian Med J. 1971 Jun;20(2):97-100 [5110487.001]
  • [Cites] Cancer. 1974 Oct;34(4):1018-22 [4417641.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):38-42 [3800603.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):513-5 [2304725.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):516-8 [2304726.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Aug;35(4):341-2 [1682183.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):217-9 [7847542.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):108-12 [15923168.001]
  • [Cites] J Obstet Gynaecol. 2006 Oct;26(7):693-5 [17071446.001]
  • [Cites] Nephrol Dial Transplant. 2007 Dec;22(12):3652-5 [17875572.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Jan;100(1):89-90 [17825829.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):181-2 [18682949.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):214-5 [14597255.001]
  • (PMID = 22791481.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027817
  •  go-up   go-down


3. Yuan ZG, Dun XY, Li YH, Hou J: Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol; 2009;2:19
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
  • Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement.
  • Optimal therapies have not been well established up to now.
  • We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission.
  • To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.
  • [MeSH-major] Boronic Acids / therapeutic use. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Neoplasms, Multiple Primary / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Bortezomib. Humans. Male. Remission Induction


Advertisement
4. Tahan I, Seale J, Edwards D: IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report. Cases J; 2008;1(1):207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report.
  • BACKGROUND: IgM multiple myeloma is rare disorder, which has clinical, laboratory and radiological manifestations that are consistent with both multiple myeloma and Waldenstrom's macroglobulinaemia.
  • Further investigations confirmed the diagnosis of IgM multiple myeloma.
  • Following localized radiotherapy and five courses of melphalan and prednisolone, the patient achieved partial remission of her myeloma.
  • Later on, the patient had disease progression in the form of rising serum IgM level and the development of multiple plasmacytomas.
  • To our knowledge, this is the second case of IgM myeloma presenting with a plasmacytoma and the first case of IgM myeloma presenting with cord compression caused by plasmacytomas.
  • CONCLUSION: Unlike other types of multiple myeloma IgM myeloma is rarely complicated by plasmacytomas.
  • However, spinal cord compression caused by plasmacytomas in this type of myeloma is extremely rare.
  • Nevertheless, the same lines of management, e.g. cytotoxic chemotherapy and local radiotherapy that are applied to other types of myeloma can be successfully utilized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 1998 Dec;59(4):302-8 [9840911.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):655-8 [18399168.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80 [18070712.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):547-51 [18275432.001]
  • [Cites] Nihon Rinsho. 2007 Dec;65(12):2268-79 [18069272.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1565-9 [16966268.001]
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):23-5 [12141951.001]
  • [Cites] Ann Hematol. 2002 Mar;81(3):136-9 [11904738.001]
  • [Cites] Med Clin (Barc). 1991 May 25;96(20):777-9 [1908542.001]
  • [Cites] Rev Med Interne. 1990 Jan-Feb;11(1):13-8 [2109345.001]
  • [Cites] Clin Lab Haematol. 2003 Jun;25(3):187-90 [12755797.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Clin Lymphoma. 2005 Mar;5(4):285-9 [15794867.001]
  • (PMID = 18831763.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566563
  •  go-up   go-down


5. Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B: Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood; 2009 Aug 13;114(7):1299-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
  • Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy.
  • With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark.
  • To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Public Health. 1984;5:385-411 [6372816.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1745-57 [11861292.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] Bone Marrow Transplant. 2005 Feb;35(3):215-24 [15543196.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1021-30 [16525139.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):158-64 [16939489.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):393-9 [17156398.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1692-700 [17023574.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2276-84 [17105813.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):176-85 [17593024.001]
  • [Cites] Oncologist. 2007 Jun;12(6):664-89 [17602058.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S207-14 [17877846.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7073-9 [18056185.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):761-81 [18070718.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2962-72 [18332230.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):355-9 [18470907.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1633-6 [18305551.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3115-21 [18492953.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3917-8 [18988869.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • (PMID = 19515721.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055819; United States / NCI NIH HHS / CA / CA 55819
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2727409
  •  go-up   go-down


6. Jenkins D, DiFrancesco L, Chaudhry A, Morris D, Glück S, Jones A, Woodman R, Brown CB, Russell J, Stewart DA: Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant; 2002 Sep;30(5):321-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients.
  • We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma.
  • Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN).
  • These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.
  • They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.
  • [MeSH-major] Lymphoproliferative Disorders / drug therapy. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antiviral Agents / administration & dosage. Diagnosis, Differential. Humans. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / therapy. Remission Induction / methods. Transplantation, Autologous / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12209355.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents
  •  go-up   go-down


7. Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, Ronco P: Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol; 2008 Sep;3(5):1339-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic, clinical, and laboratory data were assessed for each patient at the time of kidney biopsy.
  • For five patients, the diagnosis of monoclonal IgM preceded the kidney disease by 28.8 mo (range 12 to 60).
  • Seven patients had Waldenström disease, two had a small B cell non-Hodgkin lymphoma, one had an IgM-excreting multiple myeloma, one had a marginal zone B cell lymphoma, and three had an IgM-related disorder.
  • Remission of the nephrotic syndrome was attained in three of seven patients, and renal function improved after chemotherapy.
  • CONCLUSIONS: Although renal complications of IgM proliferations are rare, a wide spectrum of kidney lesions is observed, without correlation with the type of hematologic disorder.
  • [MeSH-minor] Aged. Amyloidosis / immunology. Female. Glomerulonephritis, Membranoproliferative / immunology. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell, Marginal Zone / immunology. Male. Middle Aged. Multiple Myeloma / immunology. Nephrotic Syndrome / immunology. Retrospective Studies. Treatment Outcome. Waldenstrom Macroglobulinemia / immunology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Am J Nephrol. 1985;5(1):53-8 [3918448.001]
  • [Cites] Am J Kidney Dis. 2004 May;43(5):e23-8 [15112195.001]
  • [Cites] Crit Care. 2004 Aug;8(4):R204-12 [15312219.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6542-6 [2118650.001]
  • [Cites] N Engl J Med. 1991 Jun 27;324(26):1845-51 [1904132.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):914-20 [8487054.001]
  • [Cites] Am J Hematol. 1994 Feb;45(2):171-6 [8141123.001]
  • [Cites] Clin Sci (Lond). 1994 Nov;87(5):487-91 [7874834.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jun;12(6):1256-9 [9198063.001]
  • [Cites] Clin Nephrol. 1998 May;49(5):325-7 [9617499.001]
  • [Cites] Nephrol Dial Transplant. 1998 Oct;13(10):2630-2 [9794573.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):749-57 [15806478.001]
  • [Cites] Clin Nephrol. 2005 Nov;64(5):396-9 [16312271.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):908-14 [16632032.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):e3-9 [16797380.001]
  • [Cites] Nephrol Dial Transplant. 2007 Feb;22(2):627-30 [17164317.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1342-50 [17699367.001]
  • [Cites] J Hypertens. 2007 Sep;25(9):1751-62 [17762635.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):122-5 [10665924.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):880-3 [11054074.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1058-66 [11287977.001]
  • [Cites] Am J Kidney Dis. 2001 Aug;38(2):395-9 [11479168.001]
  • [Cites] Nephron. 2002 Jul;91(3):512-5 [12119489.001]
  • [Cites] Nephron. 2002 Oct;92(2):452-5 [12218329.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):541-5 [12657941.001]
  • [Cites] Medicine (Baltimore). 2008 Mar;87(2):99-109 [18344807.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] N Engl J Med. 1970 Jul 16;283(3):123-9 [4987279.001]
  • [Cites] Arch Intern Med. 1975 Jan;135(1):40-5 [803364.001]
  • [Cites] Nephron. 1984;38(3):156-62 [6436718.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):679-85 [14602248.001]
  • (PMID = 18632851.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin M
  • [Other-IDs] NLM/ PMC2518806
  •  go-up   go-down


8. Adam Z, Krejcí M, Pour L, Feit J, Büchler T, Hájek R: IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. Wien Klin Wochenschr; 2010 May;122(9-10):311-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
  • Monoclonal gammopathy-associated IgA pemphigus is a debilitating skin disorder with inconsistent response to treatment.
  • When the monoclonal gammopathy progressed to multiple myeloma, the patient received treatment with cyclophosphamide/doxorubicin/dexamethasone but there was no clinical response.
  • Second-line therapy with a thalidomide/cyclophosphamide/dexamethasone combination led to severe exacerbation of the skin disorder.
  • However, therapy with a combination regimen that included bortezomib, cyclophosphamide and dexamethasone resulted in complete and durable remission of multiple myeloma and IgA pemphigus.
  • This suggests that bortezomib-based therapy is useful for the treatment of the rare dermatologic disorder associated with IgA gammopathy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. IgA Deficiency / prevention & control. Multiple Myeloma / drug therapy. Paraproteinemias / prevention & control. Pemphigus / prevention & control
  • [MeSH-minor] Boronic Acids / administration & dosage. Bortezomib. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Middle Aged. Pyrazines / administration & dosage. Remission Induction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1994;189 Suppl 1:111-4 [8049547.001]
  • [Cites] J Dermatol. 1992 Oct;19(10):626-8 [1491093.001]
  • [Cites] Cutis. 1998 Apr;61(4):203-8 [9564592.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Nov;17(6):725-7 [14761150.001]
  • [Cites] J Am Acad Dermatol. 2002 Dec;47(6):943-6 [12451384.001]
  • [Cites] Eur J Med Res. 2005 Mar 29;10(3):93-104 [15851375.001]
  • [Cites] Clin Exp Dermatol. 1990 Nov;15(6):433-7 [2279341.001]
  • [Cites] Clin Exp Dermatol. 2008 May;33(3):229-33 [18355359.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):890-2 [2129185.001]
  • [Cites] MMW Fortschr Med. 2007 May 10;149(19):19 [17668787.001]
  • [Cites] J Am Acad Dermatol. 1988 Nov;19(5 Pt 1):854-8 [3056995.001]
  • [Cites] Eur J Dermatol. 1999 Mar;9(2):85-94 [10066953.001]
  • [Cites] Dermatology. 1994;189 Suppl 1:115-6 [8049548.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):993-1000 [1479108.001]
  • [Cites] Dermatology. 1993;187(2):124-6 [8358100.001]
  • [Cites] Eur J Dermatol. 1999 Dec;9(8):644-6 [10586134.001]
  • [Cites] J Cutan Pathol. 2008 Aug;35(8):705-21 [18331570.001]
  • [Cites] Int J Dermatol. 2005 Oct;44(10):873-5 [16207195.001]
  • (PMID = 20559888.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, Sanz-Rodriguez C, Cabanillas F: Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer; 2001 Oct 15;92(8):2023-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic lymphoma: favorable outcome after combination chemotherapy.
  • BACKGROUND: Primary hepatic non-Hodgkin lymphoma (PHL) is a rare and difficult to diagnose lymphoproliferative disorder of unknown etiology.
  • Liver scans demonstrated either a solitary lesion or multiple lesions.
  • Combination chemotherapy was the mainstay of treatment; surgery consisted of diagnostic biopsy.
  • The complete remission rate was 83.3%, and the 5-year cause specific and failure free survival rates were 87.1% and 70.1%, respectively.
  • HCV infection did not appear to influence the outcome of therapy.
  • CONCLUSIONS: The outcome of patients with PHL who are treated with combination chemotherapy may be more favorable than that reported elsewhere.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Doxorubicin / administration & dosage. Female. Hepatitis C / complications. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11596015.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


10. Kim SJ, Kim J, Cho Y, Seo BK, Kim BS: Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol; 2007 May;37(5):382-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
  • Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy.
  • More effective treatment strategies are therefore needed for this disorder.
  • Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide.
  • The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m(2) intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4.
  • Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation.
  • Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538191.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


11. Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J: [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Vnitr Lek; 2009 Nov;55(11):1089-96
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
  • Renal biopsy specimen revealed the diagnosis of LCDD.
  • These findings confirmed the diagnosis of multiple myeloma (MM) Durie Salmon stage IB with LCDD.
  • The patient was initially treated with 4 cycles of VAD (vinkristine, adriamycine, dexamethasone) chemotherapy with no response.
  • Followed collection of peripheral haematopoietic stem cells and later high dose chemotherapy with reduced dose of melphalan 140 mg/sqm and autologous peripheral haematopoietic stem cells transplantation.
  • High dose therapy was complicated by with deterioration of renal function, creatinine increased to 600 micromol/l.
  • Follow-up examination one month after high dose chemotherapy showed complete remission, that was confirmed by further examinations.
  • In the course of the first year after high dose chemotherapy renal function gradually improved and nephrotic syndrome completely disappeared (complete kidney remission).
  • Three years after high dose chemotherapy the patient is still in complete remission of multiple myeloma and free of nephrotic syndrome, with slightly increased creatinine (160 micromol/l) that, nevertheless, has had an improving tendency over last 3 years.
  • The present case study illustrates accomplishment of complete haematological remission with high dose chemotherapy followed by autologous haematopoietic stem cells transplantation despite complete resistance of the disease to the standard chemotherapy VAD in a patient with MM and LCDD.
  • We draw the reader's attention to the possibility of nephrotoxic effects of high dose melphalan (post conditioning renal insufficiency) in patients with nephrotic syndrome caused by light chain deposits as AL-amyloid or amorphous light chains deposits (LCDD)and we document the importance of plasma free light chain detection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoglobulin Light Chains / immunology. Multiple Myeloma / therapy. Nephrotic Syndrome / physiopathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Kidney / pathology. Melphalan / administration & dosage. Melphalan / adverse effects. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017442.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  • [Number-of-references] 48
  •  go-up   go-down


12. Wang TY, Huang XO, Xu CG, Chen XC, Wang H: [Acute myelomonocytic leukemia occurred after multiple myeloma treated: a case report]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar;38(2):347-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myelomonocytic leukemia occurred after multiple myeloma treated: a case report].
  • We reported a case of multiple myeloma, who suffered from the acute myelomonocytic leukemia (AML-M4) after the chemotherapy of alkylating agent.
  • The patient had a history of multiple myeloma and was treated with the regimen of including L-Sarcolysinum and cyclophosphamide for 5 years.
  • The multiple myeloma of this patient was proved to have got the remission through bone marrow aspiration, immunofixation electrophoresis of serum, serum protein electrophoresis and detection of urine light chain.
  • During the course of supportive treatment only with blood cell and platelet transfusion, WBC count of this patient showed a rising trend and the blast cells (8%-15%) started to occur in the peripheral blood.
  • Thus, the diagnosis of multiple myeloma in remission and secondary AML-M4 was established.
  • When the chemotherapy regimen to AML was being planned for this patient, she died of massive hemorrhage of gastrointestinal tract due to thrombocytopenia and ineffectiveness.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / diagnosis. Multiple Myeloma / drug therapy
  • [MeSH-minor] Alkylating Agents / therapeutic use. Bone Marrow Cells / pathology. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441363.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alkylating Agents
  •  go-up   go-down


13. Schmitt S, Ho AD, Goldschmidt H: The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie; 2010;33(4):183-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
  • BACKGROUND: Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells.
  • This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone disease, bleeding events, kidney failure and neurological impairment.
  • LBH589 is a histone deacetylase inhibitor with an epigenetic mechanism of action and the potential for treatment in myeloma.
  • CASE REPORT: We report here about the successful treatment of a 44-year-old woman suffering from progressive myeloma with LBH589 after five different chemotherapies.
  • During the 9 years after first diagnosis of myeloma in April 2000, our patient twice underwent an autologous stem cell transplantation and was also treated with the new substances bortezomib, thalidomide and lenalidomide.
  • RESULTS: A rapid decline of myeloma activity parameters could be reached, with an approximately exponential decrease of kappa light chains in the 24-h urine.
  • As a consequence, a near-complete remission was determined after about 6 months of LBH589 treatment.
  • CONCLUSIONS: LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect.
  • [MeSH-major] Boronic Acids / administration & dosage. Histone Deacetylase Inhibitors / administration & dosage. Hydroxamic Acids / administration & dosage. Multiple Myeloma / drug therapy. Pyrazines / administration & dosage. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Bortezomib. Feasibility Studies. Female. Humans. Indoles. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389145.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 9647FM7Y3Z / panobinostat; F0P408N6V4 / lenalidomide
  •  go-up   go-down


14. Adam Z, Matýková M, Krejcí M, Pour L, Kissová J, Slechtová M, Chlupová G, Stavarová Y, Simonides J, Penka M, Mayer J, Hájek R: [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]. Vnitr Lek; 2010 Jan;56(1):67-78
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
  • [Transliterated title] Pacientka s AL-amyloidózou a závazným deficitem faktoru X je po vysokodávkované chemoterapii jiz 7 let v kompletní hematologické remisi s normální aktivitou faktoru X. Popis prípadu a prehled literatury.
  • The most frequent coagulation disorder is decreased factor X activity.
  • At that time, the patient did not satisfy the then valid Durie-Salmon criteria for multiple myeloma and thus the patient was diagnosed with primary systemic AL amyloidosis.
  • The patient's condition gradually improved following substitution therapy (Prothromplex, fresh frozen plasma and erythrocyte transfusion) and bleeding slowly ceased so that chemotherapy with VAD (vincristine, adriamycin and dexamethasone) was initiated 6 weeks after the surgery.
  • A total of 8 chemotherapy cycles were administered and complete haematological remission was achieved after the 5th cycle.
  • Administration of the 8 VAD chemotherapy cycles resulted in increased factor X activity; bleeding complications subsided completely, thereby decreasing the risk of life-threatening mucositis-associated haemorrhage.
  • Consequently, tandem high-dose chemotherapy (melphalan 100 mg/m2) with autologous haematopoietic stem cells transplantation was added to the treatment plan.
  • Treatment was completed at the beginning of 2003 and, from that time, the patient is on continuous maintenance therapy with interferon alpha.
  • Seven years from the diagnosis and 6 years from the completion of treatment the patient is in complete haematological remission, with no signs of organic damage caused by AL amyloid and with normal factor X activity.
  • Factor X activity increased at the time when complete haematological remission was achieved after 8 cycles of VAD chemotherapy to 42%, it reached 68% the second year following high-dose chemotherapy, 77% after 5 years and 85% after 7 years.
  • We had considered administration of high-dose chemotherapy in the standard regimen, i.e. following 4 cycles of VAD chemotherapy, as too high risk in the described young female patient.
  • Therefore, we administered 8 cycles of conventional chemotherapy and only after complete haematological remission and partial organ response (factor X activity increased to 42%) were achieved, we added tandem high-dose chemotherapy to the treatment.
  • We thus achieved long-term (7-years so far) complete haematological and organ remission.
  • We recommend starting treatment of high-risk transplant patients with AL amyloidosis with traditional chemotherapy regimen and, in case of positive haematological and organ treatment response, we recommend re-examination of potential benefits and risks of high-dose chemotherapy with autologous transplantation.
  • [MeSH-major] Amyloidosis / diagnosis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Factor X Deficiency / diagnosis. Multiple Myeloma / diagnosis
  • [MeSH-minor] Adult. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Factor X Deficiency.
  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184115.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  • [Number-of-references] 84
  •  go-up   go-down


15. Uskül BT, Türker H, Emre Turan F, Unal Bayraktar O, Melikoğlu A, Tahaoğlu C, Oz B: Pleural effusion as the first sign of multiple myeloma. Tuberk Toraks; 2008;56(4):439-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural effusion as the first sign of multiple myeloma.
  • Multiple myeloma (MM) is a rare disorder that affects all tissues, except reticuloendothelial tissues, and seldom causes a myelomatous pleural effusion.
  • The patient was diagnosed with IgG/k type MM and underwent chemotherapy with vincristine, doxorubicin, and prednisolone.
  • Complete regression of the pleural effusion was achieved after one round of chemotherapy, and the patient has been followed for 18 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Multiple Myeloma / diagnosis. Pleural Effusion / diagnosis
  • [MeSH-minor] Bence Jones Protein / metabolism. Bence Jones Protein / urine. Diagnosis, Differential. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123081.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


16. Rödjer S, Nilsson B, Westin J, Nordic Myeloma Study Group: Do anthracyclines have a role in the therapy of multiple myeloma? Hematol J; 2000;1(6):422-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do anthracyclines have a role in the therapy of multiple myeloma?
  • INTRODUCTION: There is a great need for alternative treatments for patients with relapsing and refractory multiple myeloma.
  • The evidence of its own efficacy in this disorder is, however, insufficient.
  • MATERIALS AND METHODS: In a multi-centre phase II study we administered oral idarubicin as a single drug in a dose of 10 mg/m(2) days 1-4 every four weeks to a total of 30 patients with relapsing (n=18) or refractory (n=12) multiple myeloma.
  • Other patients showed a very short minor response (n=1), "no change" (n=11) or progression (n=15) during the therapy.
  • Toxicity was mostly mild and the drug was fairly well tolerated.
  • CONCLUSION: Based on our experience and available data from three previously published reports, we consider idarubicin to have only a marginal effect in relapsing and refractory myeloma.
  • A review of the literature on studies of anthracylines as single-agent therapy shows that only 5% of patients (19 out of 377) show a partial response.
  • In our opinion the regular inclusion of an anthracycline in drug combinations for refractory myeloma should be reconsidered.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920223.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin
  •  go-up   go-down


17. Cem Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B: Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol; 2005 Sep;84(9):609-13
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.
  • Leukocytoclastic vasculitis (LV) is a systemic inflammatory disorder involving mostly the small vessels.
  • LV is related to a variety of clinical disorders including cryoglobulinemia and, very rarely, multiple myeloma (MM), among many others.
  • The development of LV in patients with MM has been linked to cryoglobulinemia, infections, drugs and paraneoplasia.
  • It has been speculated that myeloma patients with a poorer prognosis and progressive disease are more prone to develop LV.
  • Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties.
  • It is highly effective in the treatment of MM and other clinical disorders such as leprosy, various cancers, graft-versus-host disease and autoimmune diseases.
  • [MeSH-major] Cryoglobulinemia / complications. Multiple Myeloma / complications. Thalidomide / therapeutic use. Vasculitis, Leukocytoclastic, Cutaneous / drug therapy
  • [MeSH-minor] Dexamethasone / therapeutic use. Disease Management. Drug Therapy, Combination. Female. Humans. Middle Aged. Remission Induction


18. Adam Z, Feit J, Krejcí M, Pour L, Vasků V, Cermáková Z, Mayer J, Hájek R: [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review]. Vnitr Lek; 2009 Oct;55(10):981-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
  • [Transliterated title] IgA pemfigus provázející mnohocetný myelom vymizel pri lécbe bortezomibem (Velcade), cyklofosfamidem a dexametazonem. Popis prípadu a prehled literatury.
  • IgA pemphigus, resembling subcorneal pustulous dermatosis, represents a rare complication of IgA type monoclonal gammopathy.
  • She was first examined at our clinic in 2001 with the following conclusion "type IgA monoclonal gammopathy of unknown significance".
  • The first immunosuppressive treatment of vesicular-bullous disorder was administered in 2003 (dexamethasone 20 mg on days 1-4 and 15-18 in monthly cycles + daily cyclophosphamide 50 mg).
  • During the treatment, intensity of the skin disorder ameliorated and monoclonal IgA levels decreased to non-detectable levels.
  • Nevertheless, skin symptoms recurred immediately after dexamethasone treatment in its original intensity was terminated, even though the concentration of monoclonal immunoglobulin IgA remained below the sensitivity of quantitative detection for further 6 months (positive immunofixation only).
  • Six rituximab 600 mg infusions were administered in a weekly interval after stopping cyclophosphamide and dexamethasone to prevent early recurrence of skin symptoms but this treatment was without any lasting effect.
  • Transformation into multiple myeloma was identified in 2007.
  • First line treatment (cyclophosphamide, adriamycin and dexamethasone - CAD) remained without any haematological or dermatological treatment response.
  • Second line treatment (thalidomide, cyclophosphamide and dexamethasone - CTD) brought about significant deterioration of skin symptoms up to the clinical picture of erythrodermia.
  • Third line treatment (bortezomib 1.3 mg/sqm i.v. on days 1,4, 8 and 15, cyclophosphamide 50 mg daily and dexamethasone 20 mg on days 1-4 and 15-18 in 28-day cycles - VCD) resulted in rapid decline in monoclonal immunoglobulin IgA concentrations immediately following the first cycle and to negative immunofixation after 5 cycles.
  • The patient has had no skin symptoms from the third cycle of this treatment and complete skin and haematological remission has been maintained for 12 months after completion of bortezomib-containing treatment.
  • Combined treatment containing bortezomib has proven useful in the treatment of IgA pemphigus accompanying monoclonal gammopathy of uncertain significance transformed into multiple myeloma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoglobulin A / blood. Multiple Myeloma / drug therapy. Paraproteinemias / complications. Pemphigus / pathology
  • [MeSH-minor] Aged. Boronic Acids / administration & dosage. Bortezomib. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Pyrazines / administration & dosage. Skin Diseases, Vesiculobullous / complications. Skin Diseases, Vesiculobullous / diagnosis


19. Kovacsovics T: [Current treatment of AL amyloidosis]. Rev Med Suisse Romande; 2000 Oct;120(10):771-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current treatment of AL amyloidosis].
  • [Transliterated title] Approches actuelles du traitement de l'amyloïdose AL.
  • AL amyloidosis is a plasma cell disorder characterized by the tissue accumulation of immunoglobulin light chains.
  • Therefore, current treatment strategies in AL amyloidosis aim at reducing the plasma cell clones, using chemotherapy regimens applied in multiple myeloma.
  • A combination of melphalan and prednisone is the standard therapy of AL amyloidosis, but its results remain disappointing.
  • Intensive chemotherapy regimens, with high-dose melphalan followed by peripheral blood stem cell transplantation, lead to increased response rates and improved survival, but are complicated by severe short term morbidity and mortality.
  • [MeSH-major] Amyloid. Amyloidosis / classification. Amyloidosis / therapy. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Hematopoietic Stem Cell Transplantation. Melphalan / therapeutic use. Prednisone / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Humans. Morbidity. Prognosis. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109905.001).
  • [ISSN] 0035-3655
  • [Journal-full-title] Revue médicale de la Suisse romande
  • [ISO-abbreviation] Rev Med Suisse Romande
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Amyloid; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / amyloid protein AL; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 25
  •  go-up   go-down


20. Khaliq W, Uzoaru I, Konchanin RP, Sapiente RA, Egner JR: Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology (Williston Park); 2010 Aug;24(9):832-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma.
  • Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue.
  • A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder.
  • The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles.
  • The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP.
  • The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma.
  • Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Plasmacytoma. Radiotherapy. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Biopsy. Cystoscopy. Dexamethasone / administration & dosage. Humans. Male. Radiation Tolerance. Remission Induction. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives. Treatment Failure. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):836 [20923038.001]
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):838 [20923039.001]
  • (PMID = 20923037.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


21. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA: Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis; 2005 Aug;46(2):278-82
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The natural history of the condition varies, and although it may be responsive to therapy, FSGS is an important cause of end-stage renal disease.
  • FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder.
  • RESULTS: A cohort of 13 patients with "idiopathic" FSGS and a monoclonal plasma cell disorder were identified.
  • Four patients had myeloma, and 9 patients had monoclonal gammopathy of undetermined significance.
  • Patients treated for myeloma experienced improvement in their renal lesion, and the latter relapsed when the myeloma relapsed.
  • Therapy for the underlying plasma cell disorder can lead to resolution of FSGS.
  • The emerging molecular pathogenesis of both FSGS and myeloma also provides potential mechanisms that link the 2 conditions together.
  • Thus, physicians must rule out a plasma cell proliferative disorder in patients with FSGS before concluding that the renal lesion is idiopathic.
  • Moreover, FSGS may respond favorably after the underlying plasma cell disorder is controlled.
  • [MeSH-minor] Aged. Amyloidosis / etiology. Amyloidosis / pathology. Antibodies, Monoclonal / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cohort Studies. Combined Modality Therapy. Comorbidity. Cytokines / physiology. Databases, Factual. Dexamethasone / administration & dosage. Female. Humans. Immunoglobulin Light Chains / metabolism. Kidney / metabolism. Kidney / pathology. Male. Melphalan / administration & dosage. Metabolic Clearance Rate. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Multiple Myeloma / physiopathology. Multiple Myeloma / therapy. Myeloma Proteins / metabolism. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Prevalence. Proteinuria / etiology. Recurrence. Remission Induction. Retrospective Studies. Time Factors. Vasculitis / complications. Vasculitis / pathology

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112046.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cytokines; 0 / Immunoglobulin Light Chains; 0 / Myeloma Proteins; 7S5I7G3JQL / Dexamethasone; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 28
  •  go-up   go-down


22. Revenga F, Aguilar C, González R, Paricio JF, Sanz P, Santos I: Cryofibrinogenaemia with a good response to stanozolol. Clin Exp Dermatol; 2000 Nov;25(8):621-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 63-year-old patient with an IgA-kappa multiple myeloma in complete remission who developed necrotic lesions on both ears and papular, purpuric lesions on his legs and cheeks.
  • Initial differential diagnosis included perniosis and skin necrosis secondary to interferon treatment but subsequent investigation revealed cryofibrinogenaemia as the underlying cause.
  • Stanozolol therapy, 2 mg/12 h, achieved a complete clearance of the skin lesions.
  • Stanozolol is useful as first line therapy for this disorder.
  • [MeSH-major] Anabolic Agents / therapeutic use. Cryoglobulinemia / drug therapy. Stanozolol / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Diagnosis, Differential. Humans. Interferon-alpha / adverse effects. Male. Middle Aged. Multiple Myeloma / drug therapy

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • Hazardous Substances Data Bank. STANOZOLOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11167976.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 4R1VB9P8V3 / Stanozolol
  •  go-up   go-down


23. Chim CS: Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome. Cancer Chemother Pharmacol; 2008 Jun;62(1):181-2
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy. Tumor Lysis Syndrome / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846773.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down






Advertisement